Semler Scientific®

Transforming Healthcare for a Brighter Future

Supporting the Early Detection of Chronic Diseases

Forward- Looking Statements

This presentation includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believe,” “estimate,” “anticipate,” “expect,” “plan,” “intend,” “may,” “could,” “might,” “will,” “should,” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. Such forward-looking statements appear in a number of places throughout this presentation and include express and implied statements regarding expansion of the healthcare business, seeking a new 510(k) clearance for QuantaFlo® with expanded indications for use, purchase of additional bitcoin, value of bitcoin and ability to execute on the Bitcoin treasury strategy, the market opportunity for our products, new products and service offerings, as well as our plans for maximizing stockholder returns and our goals for the year, among others. These statements are based on our current intentions, beliefs, projections, outlook, analyses or current expectations.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, the industry in which we operate and the trends that may affect the industry or us, as well as our new bitcoin strategy. Our results of operations, financial condition, liquidity, prospects, growth and strategies depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation as a result of, among other factors, the factors referenced in the “Risk Factors” section of our form 10-Q as filed with the SEC on November 5, 2024, risks inherent with investing in Bitcoin, including Bitcoin’s volatility, risk of implementing a new Bitcoin treasury strategy, the CMS 2024 Medicare Advantage and Part D Final Rate Announcement and the change in the reimbursement landscape, our ability to obtain a new 510(k) clearance for expanded indications, and the seasonality observed in our variable (fee per test) revenues, and other geopolitical events that may impact our supply chain, such as the Russian invasion of Ukraine, recent hostilities involving Israel, and other geopolitical conflicts as well as inflation. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this presentation, they may not be predictive of results of developments in future periods. Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation, except as required by law.

You should read carefully our “Cautionary Note Regarding Forward-Looking Statements and Industry Data” and the factors described in the “Risk Factors” sections of the Annual Report to better understand the risks and uncertainties inherent in our business.

Semler Scientific, Inc. Highlights

(in millions of U.S. Dollars)

Bitcoin Holdings

1,873 as of 12/04/24

- Acquired 2,084 bitcoins as of 12/15/24 at a total cost of $168.8 million
- Total market value of bitcoin holdings of $214.8 million, as of 12/15/24
- Able to use cash flows from operating business to accumulate bitcoins, which serve as our primary treasury reserve asset

Revenues

$68.2M FY 12/31/23

$43.9M 9 - mos 9/30/24

- Solid track record of profitability
- Recurring and high margin SAAS revenue model
- Net cash provided by operations of $18.3 million 9-mos 9/30/24
- Cash, cash equivalents and restricted cash balance of $6.7 million as of 9/30/24

Disruptive, Paradigm - shifting Business with Large Opportunity

1. Bitcoin treasury strategy with opportunity to create stockholder value through strategic bitcoin accumulation
2. Technology to bring cardiovascular testing to the front lines of medicine (clinics and home cares)
3. High-leverage distribution model selling to Health Insurance Plans, Health Risk Assessment (HRAs) companies, and other emerging customers
4. Software as a service (SAAS) recurring-revenue subscription licensing model, with a large and underpenetrated TAM

Stockholder Value Creation Priorities

Maximize Stockholder Returns

Bitcoin Treasury Strategy

Use cash generated from operations and opportunistically leverage capital markets and invest proceeds in bitcoin

Cash Generation

Core business selling QuantaFlo is cash generative which may support future bitcoin purchases

QuantaFlo®

SUPPORTS IN THE DIAGNOSIS

for Peripheral Arterial Disease (PAD)

MARKET INTRODUCTION

2011

REGULATORY STATUS

FDA Cleared

POINT OF SERVICE

Clinics (primary & specialty) & home care

SOFTWARE/ HARDWARE

QuantaFlo Application + sensor
Works on standard PC/tablet

TEST ADMINISTERED BY

Medical Aide

PRICING MODEL

Software as a Service licenses

QuantaFlo Aids in the Diagnosis of PAD



80 MILLION

We believe there are more than 80 million U.S. patients who could be tested based on the ACC/AHA guidelines[1,2]

COMORBIDITIES

Often had comorbidities such as heart failure, diabetes, and renal failure

PAD

is a condition where the arteries serving the extremities (peripheries) narrow and reduce blood flow

WHO IS AT RISK?[1]

- Age ≥65 years
- Age 50-65 with risk factors (e.g., diabetes mellitus, history of smoking, hyperlipidemia, hypertension) or family history[2]
- Age <50 with diabetes and one additional risk factor

Delaying Testing for PAD Allows Progression

"Detecting previously undiagnosed peripheral artery disease is a way to risk stratify a population that would benefit from further cardiovascular risk management"[3]



There is potential to realize cost-savings by reducing cardiovascular event rates and deploying population-based PAD risk management strategies.

Recent Independent Clinical Studies Supports Use of QuantaFlo

Two independently conducted; peer-reviewed studies published in 2022 analyzed screening tests using QuantaFlo


AJPM FOCUS

INCLUSIVITY IN PEOPLE, METHODS, AND OUTCOMES

RESEARCH ARTICLE

Peripheral Artery Disease Screening in the Community and 1-Year Mortality, Cardiovascular Events, and Adverse Limb Events

The Nevada peripheral artery disease screening effort in a Medicare Advantage population and subsequent mortality and major adverse cardiovascular event risk

- The “HouseCalls Program” published in the AJPM Focus tested 192,500 patients in their home[3]
- The “Nevada Paper” published in the Journal of Vascular Surgery tested 13,971 patients in clinics[4]
  - ~30% of asymptomatic patients tested positive for PAD
  - The risk associated with detecting PAD was substantial with increased risk of all-cause mortality or morbidity at one and three years
- The studies underscore the potential for nationwide programs in clinics and at home, allowing stratification for further cardiovascular risk management

Large Enterprise Customers Base

Favorable Customer Economics

Current or target customers includes health insurance plans, home risk assessment companies, delegated medical groups, hospitals and retail clinics

Semler Scientific®

Transforming Healthcare for a Brighter Future

For additional information or questions, please reach out to the contact below:

ir@semlerscientific.com

semlerscientific.com

References

1. Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., Lookstein, R., Misra, S., Mureebe, L., Olin, J. W., Patel, R. A. G., Regensteiner, J. G., Schanzer, A., Shishehbor, M. H., Stewart, K. J., Treat-Jacobson, D., … Walsh, M. E. (2017). 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, *69*(11), 1465–1508. https://doi.org/10.1016/j.jacc.2016.11.008
2. Fang, J., Yang, Q., Hong, Y., & Loustalot, F. (2012). Status of cardiovascular health among adult Americans in the 50 states and the District of Columbia, 2009. *Journal of the American Heart Association*, *1*(6). https://doi.org/10.1161/jaha.112.005371
3. Smolderen K.G., Ameli, O., Chaisson, C.E., Heath, K., & Mena-Hurtado, C. (2022). Peripheral artery disease screening in the community and 1-year mortality, cardiovascular events, and adverse limb events. *AJPM Focus*, *1*(1), 100016. https://doi.org/10.1016/j.focus.2022.100016
4. Smolderen, K. G., Heath, K., Scherr, T., Bauzon, S. R., Howell, A. N., & Mena-Hurtado, C. (2022). The Nevada peripheral artery disease screening effort in a Medicare Advantage population and subsequent mortality and major adverse cardiovascular event risk. *Journal of vascular surgery*, *75*(6), 2054–2064.e3. https://doi.org/10.1016/j.jvs.2022.01.134